Diverse biomarkers, including PSA, BRCA mutations, PSMA, and AR-V7, guide treatment decisions in advanced prostate cancer management. Emerging biomarkers like ctDNA and PTEN loss offer predictive and ...

"We need to promote further research and guidelines for safe use of these natural products, because I think we're missing out if we don't monitor them," says Channing J. Paller, MD. In this video, ...

Precision-based care is enhancing urologic diagnostics, reducing unnecessary interventions, and improving treatment personalization, particularly in prostate cancer. Workforce shortages and an aging ...

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine. In this video, from the 2025 Desai Sethi Urology Institute Urology on the Beach meeting, Dayna R. Smerina ...

"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD. In this video, Matthew J. Mutter, MD, highlights ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

Ibex Prostate Detect uses AI to analyze prostate biopsy images, generating heatmaps and alerts to assist pathologists in identifying missed tumors. The software achieved a 99.6% positive predictive ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R.

Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection through urine ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Prior to recent therapeutic innovations in the bladder space, what challenges or unmet needs did you face when treating ...